Payment overview · 2025
General Payments
$992.22
8 reported records · 8 companies
Healthcare provider profile · identity verified
Saima Shafi, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · EASTON, PA · NPI 1285655134
Verified facts
What the public records show
CMS Open Payments records show Saima Shafi, M.D. received $992.22 in general payments during 2025 across 8 reported records.
Janssen Biotech, Inc. accounted for 12.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Xarelto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 425 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $125.00 | 12.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $124.74 | 12.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $124.74 | 12.6% | 1 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $124.74 | 12.6% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $124.74 | 12.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $124.74 | 12.6% | 1 | 2025 |
| Pharmacosmos Therapeutics Inc. | Unresolved — no canonical attribution shown | $123.82 | 12.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $119.70 | 12.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $992.22 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CARVYKTI Normalized: carvykti |
Drug | Janssen Biotech, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| RYBREVANT Normalized: rybrevant |
Drug | Janssen Biotech, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc. | $124.74 | 1 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Otsuka America Pharmaceutical, Inc. | $124.74 | 1 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $124.74 | 1 | 2025 |
Source payment records
|
|||||
| EPKINLY Normalized: epkinly |
Drug | ABBVIE INC. | $124.74 | 1 | 2025 |
Source payment records
|
|||||
| PADCEV Normalized: padcev |
Biological | PFIZER INC. | $124.74 | 1 | 2025 |
Source payment records
|
|||||
| MONOFERRIC Normalized: monoferric |
Drug | Pharmacosmos Therapeutics Inc. | $123.82 | 1 | 2025 |
Source payment records
|
|||||
| BENLYSTA Normalized: benlysta |
Biological | GlaxoSmithKline, LLC. | $119.70 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
90 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
425 | 63 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 459 | 130 |
| Eliquis | Apixaban | 425 | 63 |
| Gabapentin | Gabapentin | 284 | 71 |
| Amlodipine Besylate | Amlodipine Besylate | 278 | 63 |
| Metoprolol Tartrate | Metoprolol Tartrate | 257 | 54 |
| Furosemide | Furosemide | 254 | 64 |
| Levothyroxine Sodium | Levothyroxine Sodium | 235 | 59 |
| Potassium Chloride | Potassium Chloride | 213 | 49 |
| Pantoprazole Sodium | Pantoprazole Sodium | 177 | 64 |
| Metoprolol Succinate | Metoprolol Succinate | 167 | 47 |
| Buspirone Hcl | Buspirone Hcl | 165 | 31 |
| Lisinopril | Lisinopril | 165 | 37 |
| Duloxetine Hcl | Duloxetine Hcl | 152 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 110 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 109 | 26 |
| Levetiracetam | Levetiracetam | 108 | 18 |
| Metformin Hcl | Metformin Hcl | 105 | 33 |
| Sertraline Hcl | Sertraline Hcl | 104 | 18 |
| Torsemide | Torsemide | 101 | 41 |
| Mirtazapine | Mirtazapine | 96 | 25 |
| Carvedilol | Carvedilol | 95 | 24 |
| Trazodone Hcl | Trazodone Hcl | 92 | 23 |
| Xarelto | Rivaroxaban | 90 | suppressed |
| Omeprazole | Omeprazole | 89 | 38 |
| Losartan Potassium | Losartan Potassium | 86 | 31 |
| Prednisone | Prednisone | 84 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 84 | 31 |
| Memantine Hcl | Memantine Hcl | 77 | 12 |
| Donepezil Hcl | Donepezil Hcl | 76 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 71 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 68 | suppressed |
| Simvastatin | Simvastatin | 63 | 14 |
| Allopurinol | Allopurinol | 48 | 12 |
| Finasteride | Finasteride | 47 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 47 | 11 |
| Januvia | Sitagliptin Phosphate | 45 | suppressed |
| Risperidone | Risperidone | 45 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 43 | suppressed |
| Methocarbamol | Methocarbamol | 42 | 16 |
| Amiodarone Hcl | Amiodarone Hcl | 39 | suppressed |
| Baclofen | Baclofen | 39 | suppressed |
| Restasis | Cyclosporine | 37 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 35 | suppressed |
| Latanoprost | Latanoprost | 35 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 34 | suppressed |
| Famotidine | Famotidine | 34 | 17 |
| Jardiance | Empagliflozin | 34 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 32 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 32 | 15 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 31 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 30 | 11 |
| Sulfasalazine | Sulfasalazine | 30 | suppressed |
| Topiramate | Topiramate | 30 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 29 | 11 |
| Ezetimibe | Ezetimibe | 28 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 28 | 11 |
| Nystatin | Nystatin | 28 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | suppressed |
| Aripiprazole | Aripiprazole | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Methotrexate | Methotrexate Sodium | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 25 | 16 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 24 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Securesafe Pen Needle | Pen Needle, Diabetic, Safety | 22 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 22 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Lubiprostone | Lubiprostone | 21 | suppressed |
| Atenolol | Atenolol | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | 14 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 20 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 17 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 16 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 15 | suppressed |
| Hydroxyurea | Hydroxyurea | 15 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 12 | suppressed |
| Azithromycin | Azithromycin | 12 | 11 |
| Cephalexin | Cephalexin | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Cyclosporine | Cyclosporine | 12 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 12 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 11 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $992.22 · 8 records | Janssen Biotech, Inc. | ABILIFY ASIMTUFII, ABILIFY MAINTENA, BENLYSTA, BRIXADI, CARVYKTI, EPKINLY, MONOFERRIC, PADCEV, RYBREVANT | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error